CDA and acute myeloid leukemia: Guadecitabine is resistant to cytidine deaminase and has been tested in a phase 2 clinical trial of 107 newly diagnosed AML patients and a phase 2 clinical trial of fifty-five adult relapsed/refractory AML and MDS patients.